AstraZeneca (AZN)
(Delayed Data from NSDQ)
$75.88 USD
+0.40 (0.53%)
Updated Apr 30, 2024 04:00 PM ET
After-Market: $75.88 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Price, Consensus and EPS Surprise
AZN 75.88 +0.40(0.53%)
Will AZN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for AZN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AZN
Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
Fusion (FUSN) to Report Q1 Earnings: Here's What to Expect
AZN: What are Zacks experts saying now?
Zacks Private Portfolio Services
AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up
Other News for AZN
US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Novo, Teva, AstraZeneca issued FTC warnings over ‘bogus’ patents
FTC expands patent listing challenges for drugs
J&J, Bristol Myers latest to lose bids to halt Medicare price negotiations
Analysts Offer Insights on Healthcare Companies: AstraZeneca (AZN), Accolade (ACCD) and Morphic Holding (MORF)